Literature DB >> 1980339

Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.

E Klein1, L Di Renzo, E Yefenof.   

Abstract

The complement receptor CR3 molecule functions in direct intercellular contacts mediated by its beta chain, CD18. Similarly to the Fc receptor (CD16), CR3 is a marker of human natural killer cells. We have shown that opsonization of NK targets with iC3b leads to their increased lytic sensitivity. Opsonization could be achieved by incubating certain B and T cell lines in human serum. The expression of CR2 was a prerequisite for C3 fragment fixation. The CR2 negative cell line, P3HR1 could be opsonized by incubation in human serum when induced to express the EBV envelope glycoprotein gp350. C3b or iC3b could also be deposited artificially on cell surfaces by chemical coupling to surface reactive antibodies. Similarly to the function of macrophages and monocytes, contact with opsonized targets exclusively through the iC3b binding site of CR3 did not seem to trigger NK function. We attempted to clarify the functional role of other CR3 ligands. The beta chain of the molecule, CD18, was essential to the NK effect. The NK targets did not seem to interact with the beta-glucan binding epitope on the alpha chain of CR3, CD11b. On the other hand, the cytolytic function could be enhanced through this epitope with the appropriate ligand.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980339     DOI: 10.1016/0161-5890(90)90041-w

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 3.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 4.  Complement in monoclonal antibody therapy of cancer.

Authors:  Laura M Rogers; Suresh Veeramani; George J Weiner
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 5.  Interactions between natural killer cells, cortisol and prolactin in malaria during pregnancy.

Authors:  Elie Mavoungou
Journal:  Clin Med Res       Date:  2006-03

Review 6.  CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.

Authors:  G D Ross; V Vĕtvicka
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

8.  Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.

Authors:  Srinivas Mamidi; Marc Cinci; Max Hasmann; Volker Fehring; Michael Kirschfink
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

9.  Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.

Authors:  Munetoshi Ando; Keiko Nagata; Kaito Nihira; Yui Suzuki; Yutaka Kanda; Maiko Adachi; Tsuguo Kubota; Naoya Kameyama; Mariko Nakano; Hiroshi Ando; Kazuya Yamano; Toshihiko Ishii; Ryuichiro Nakai; Kazuyasu Nakamura
Journal:  Transl Oncol       Date:  2017-07-12       Impact factor: 4.243

Review 10.  The effects of beta-glucan on human immune and cancer cells.

Authors:  Godfrey Chi-Fung Chan; Wing Keung Chan; Daniel Man-Yuen Sze
Journal:  J Hematol Oncol       Date:  2009-06-10       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.